Linezolid Fresenius Kabi (Linezolid)

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex needed for translation. This action stops bacterial growth (bacteriostatic) against most Gram‑positive organisms, including strains resistant to other antibiotic classes.

The dosage and duration of Linezolid Fresenius Kabi are determined by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and other clinical factors. No standard dose is provided here; the prescriber sets the appropriate regimen.

Safety data for linezolid in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Linezolid and vancomycin both target Gram‑positive bacteria, but linezolid is an oral and intravenous oxazolidinone, while vancomycin is a glycopeptide given intravenously. Linezolid offers a convenient IV-to-oral switch and is active against some vancomycin‑resistant strains, but it carries a different safety profile, including risk of thrombocytopenia and serotonin syndrome.

Linezolid Fresenius Kabi should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging until use. Once reconstituted, follow the manufacturer’s instructions for stability and discard any unused portion after the recommended time.

The product is supplied as an intravenous solution and is administered by slow infusion into a vein, typically over 30 to 60 minutes. Administration should be performed by qualified healthcare personnel in a clinical setting, following aseptic technique and the prescribing information.

Serious risks include thrombocytopenia, peripheral or optic neuropathy, and serotonin syndrome, especially when combined with serotonergic drugs. Patients should be monitored regularly for blood‑cell counts, visual changes, and signs of serotonin excess such as agitation, fever, or muscle rigidity.

Linezolid is contraindicated in patients with known hypersensitivity to linezolid or any component of the formulation. Caution is advised for individuals taking serotonergic agents, those with pre‑existing hematologic disorders, or patients with severe hepatic impairment, unless the prescriber determines the benefits outweigh the risks.